FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3135729218> ?p ?o ?g. }

• W3135729218 endingPage "1040" @default.
• W3135729218 startingPage "1040" @default.
• W3135729218 abstract "Anti-PD-1 antibodies prolong survival of performance status (PS) 0–1 advanced non-small-cell lung cancer (aNSCLC) patients. Their efficacy in PS 3–4 patients is unknown. Conse- cutive PS 3–4 aNSCLC patients receiving compassionate nivolumab were accrued by 12 French thoracic oncology departments, over 24 months. Overall survival (OS) was calculated using the Kaplan-Meier method. Prognostic variables were assessed using Cox proportional hazards models. Overall, 35 PS 3–4 aNSCLC patients (median age 65 years) received a median of 4 nivolumab infusions (interquartile range [IQR], 1–7) as first- (n = 6) or second-line (n = 29) therapy. At a median of 52-month follow-up (95%CI, 41–63), 32 (91%) patients had died. Median progression-free survival was 2.1 months (95%CI, 1.1–3.2). Median OS was 4.4 months (95%CI, 0.5–8.2). Overall, 20% of patients were alive at 1 year, and 14% at 2 years. Treatment-related adverse events occurred in 8/35 patients (23%), mostly of low-grade. After adjustment, brain metastases (HR = 5.2; 95%CI, 9–14.3, p = 0.001) and <20 pack-years (HR = 4.8; 95%CI, 1.7–13.8, p = 0.003) predicted worse survival. PS improvement from 3–4 to 0–1 (n = 9) led to a median 43-month (95%CI, 0–102) OS. Certain patients with very poor general condition could derive long-term benefit from nivolumab salvage therapy." @default.
• W3135729218 created "2021-03-15" @default.
• W3135729218 creator A5007309998 @default.
• W3135729218 creator A5020254907 @default.
• W3135729218 creator A5023080520 @default.
• W3135729218 creator A5028897044 @default.
• W3135729218 creator A5029701357 @default.
• W3135729218 creator A5036606203 @default.
• W3135729218 creator A5042208385 @default.
• W3135729218 creator A5043441875 @default.
• W3135729218 creator A5044886899 @default.
• W3135729218 creator A5053712155 @default.
• W3135729218 creator A5055798090 @default.
• W3135729218 creator A5056853165 @default.
• W3135729218 creator A5058100097 @default.
• W3135729218 creator A5063103135 @default.
• W3135729218 creator A5075914427 @default.
• W3135729218 creator A5077305357 @default.
• W3135729218 creator A5082798685 @default.
• W3135729218 date "2021-03-02" @default.
• W3135729218 modified "2023-10-15" @default.
• W3135729218 title "Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients" @default.
• W3135729218 cites W1972053944 @default.
• W3135729218 cites W1981049999 @default.
• W3135729218 cites W2016004006 @default.
• W3135729218 cites W2029688289 @default.
• W3135729218 cites W2058408106 @default.
• W3135729218 cites W2060526769 @default.
• W3135729218 cites W2070057564 @default.
• W3135729218 cites W2104347254 @default.
• W3135729218 cites W2111191667 @default.
• W3135729218 cites W2144499377 @default.
• W3135729218 cites W2154094376 @default.
• W3135729218 cites W2156353875 @default.
• W3135729218 cites W2198093519 @default.
• W3135729218 cites W2312481768 @default.
• W3135729218 cites W2527905628 @default.
• W3135729218 cites W2567564314 @default.
• W3135729218 cites W2589663961 @default.
• W3135729218 cites W2635951006 @default.
• W3135729218 cites W2739918405 @default.
• W3135729218 cites W2759963646 @default.
• W3135729218 cites W2765314233 @default.
• W3135729218 cites W2793456508 @default.
• W3135729218 cites W2797675588 @default.
• W3135729218 cites W2896274372 @default.
• W3135729218 cites W2925446385 @default.
• W3135729218 cites W2946456966 @default.
• W3135729218 cites W2961994293 @default.
• W3135729218 cites W2969808986 @default.
• W3135729218 cites W2982040065 @default.
• W3135729218 cites W2982610601 @default.
• W3135729218 cites W3005530155 @default.
• W3135729218 cites W3010178462 @default.
• W3135729218 cites W3012342269 @default.
• W3135729218 cites W3026844837 @default.
• W3135729218 cites W3094376062 @default.
• W3135729218 doi "https://doi.org/10.3390/cancers13051040" @default.
• W3135729218 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7958129" @default.
• W3135729218 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33801285" @default.
• W3135729218 hasPublicationYear "2021" @default.
• W3135729218 type Work @default.
• W3135729218 sameAs 3135729218 @default.
• W3135729218 citedByCount "11" @default.
• W3135729218 countsByYear W31357292182021 @default.
• W3135729218 countsByYear W31357292182022 @default.
• W3135729218 countsByYear W31357292182023 @default.
• W3135729218 crossrefType "journal-article" @default.
• W3135729218 hasAuthorship W3135729218A5007309998 @default.
• W3135729218 hasAuthorship W3135729218A5020254907 @default.
• W3135729218 hasAuthorship W3135729218A5023080520 @default.
• W3135729218 hasAuthorship W3135729218A5028897044 @default.
• W3135729218 hasAuthorship W3135729218A5029701357 @default.
• W3135729218 hasAuthorship W3135729218A5036606203 @default.
• W3135729218 hasAuthorship W3135729218A5042208385 @default.
• W3135729218 hasAuthorship W3135729218A5043441875 @default.
• W3135729218 hasAuthorship W3135729218A5044886899 @default.
• W3135729218 hasAuthorship W3135729218A5053712155 @default.
• W3135729218 hasAuthorship W3135729218A5055798090 @default.
• W3135729218 hasAuthorship W3135729218A5056853165 @default.
• W3135729218 hasAuthorship W3135729218A5058100097 @default.
• W3135729218 hasAuthorship W3135729218A5063103135 @default.
• W3135729218 hasAuthorship W3135729218A5075914427 @default.
• W3135729218 hasAuthorship W3135729218A5077305357 @default.
• W3135729218 hasAuthorship W3135729218A5082798685 @default.
• W3135729218 hasBestOaLocation W31357292181 @default.
• W3135729218 hasConcept C10515644 @default.
• W3135729218 hasConcept C119060515 @default.
• W3135729218 hasConcept C121608353 @default.
• W3135729218 hasConcept C126322002 @default.
• W3135729218 hasConcept C141071460 @default.
• W3135729218 hasConcept C143998085 @default.
• W3135729218 hasConcept C197934379 @default.
• W3135729218 hasConcept C2776256026 @default.
• W3135729218 hasConcept C2777701055 @default.
• W3135729218 hasConcept C2780030458 @default.
• W3135729218 hasConcept C50382708 @default.
• W3135729218 hasConcept C71924100 @default.

• next